Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT for Treatment of Schizophrenia in Adolescents (Japan, Phase 3)
jRCT2011250065Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing KarXT with Placebo (2 arms). Primary endpoint: Change From Baseline in PANSS Total Score at Week 5. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2011250065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250065.